E. Puymirat, Acute Myocardial Infarction: Changes in Patient Characteristics, Management, and 6-Month Outcomes Over a Period of 20 Years in the FAST-MI Program (French Registry of Acute ST-Elevation or Non-ST-elevation Myocardial Infarction, 1995.

R. Marco, ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, European Heart Journal, p.281, 2015.

I. Borja, ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation, European Heart Journal, p.151, 2017.

D. Vorchheimer, Inflammatory markers in coronary artery disease. Let prevention douse the flames, JAMA, vol.286, pp.2154-2160, 2001.

P. M. Ridker, High-sensitivity C-reactive protein. Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease, Circulation, vol.103, pp.1813-1821, 2001.

P. M. Ridker, Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events, N Engl J Med, vol.347, pp.1557-70, 2002.

P. M. Ridker, Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels, Circulation, vol.98, pp.839-883, 1998.

M. A. Albert, Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study, JAMA, vol.286, pp.64-70, 2001.

P. M. Ridker, Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia, Circulation, vol.103, pp.1191-1194, 2001.

P. M. Ridker, Rosuvastatin to prevent vascular events in men and women with elevated C-reactiv protein, N Eng J Med, vol.359, pp.2195-207, 2008.

, Myocardial infarction redefined a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction, Eur Heart J, vol.21, pp.1502-1515, 2000.

P. Kamine and J. Richer, Atlas d'anatomie humaine 6ème édition

P. K. Shah, Inflammation and plaque vulnerability, Cardiovasc Drugs Ther, vol.23, pp.31-40, 2009.

D. E. Newby, Triggering of acute myocardial infarction: beyond the vulnerable plaque, Heart, vol.96, pp.1-247, 2010.

N. Hiari, FDG PET imaging and cardiovascular inflammation, Curr Cardiol Rep, vol.13, pp.43-51, 2011.

P. Libby, Pathophysiology of coronary artery disease, Circulation, vol.111, pp.3481-3489, 2005.

R. Ross, Atherosclerosis-an inflammatory disease, N Engl J Med, vol.340, pp.115-141, 1999.

S. Rajagopalan, Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability, J Clin Invest, vol.98, pp.2-572, 1996.

R. Ross, Atherosclerosis an inflammatory disease, N Engl J Med, vol.340, pp.115-126, 1999.

J. D. Neaton, Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group, Arch Intern Med, vol.152, pp.1490-1500, 1992.

Z. Reiner, /EAS Guidelines for the manage-ment of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) the European Atherosclerosis Society (EAS), Eur Heart J, vol.32, pp.1769-1818, 2011.

B. Mihaylova, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials, Lancet, vol.380, pp.581-590, 2012.

P. W. Wilson, Prediction of coronary heart disease using risk factor categories, Circulation, vol.97, pp.1837-1884, 1998.

D. Backer and G. , Third joint task force of european and other societies on cardiovascular disease prevention in clinical practice. European guidelines on cardiovascular disease prevention in clinical practice, Eur Heart J, vol.24, pp.1601-1611, 2003.

S. Yusuf, INTERHEART study investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries, Lancet, vol.364, pp.937-52, 2004.

G. Assmann, Simple scoring scheme for calculating the risk of coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study, Circulation, vol.105, pp.320-325, 2002.

F. Walter, Quels marqueurs biologiques de l'athérosclérose et du risque cardiovasculaire conseiller ?, Revue Médicale Suisse, vol.4, p.237, 2008.

P. M. Ridker, Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men, N Engl J Med, vol.336, pp.973-982, 1997.

P. M. Ridker, C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women, N Engl J Med, vol.342, pp.836-879, 2000.

L. M. Biasucci, Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability, Circulation, vol.99, pp.855-60, 1999.

B. Lindahl, Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary disease, N Engl J Med, vol.343, pp.1139-1186, 2000.

F. Haverkate, Production of C-reactive protein and risk of coronary events in stable and unstable angina, Lancet, vol.349, pp.462-468, 1997.

E. R. Ferreiro-?, Independent prognostic value of elevated C-reactive protein in unstable angina, Circulation, vol.100, pp.1958-63, 1999.

M. A. Mendall, C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men, Eur Heart J, vol.21, pp.1584-90, 2000.

P. M. Ridker, Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events, N Engl J Med, vol.347, pp.1557-70, 2002.

E. Agnethe, Joint Effect of Carotid Plaque and C-Reactive Protein on First-Ever Ischemic Stroke and Myocardial Infarction ?, Journal of the American Heart Association, vol.7, p.8951, 2018.

P. M. Ridker, Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels. Mars, Circulation, vol.98, pp.839-844, 2018.

T. A. Pearson, Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association, Circulation, vol.107, issue.3, pp.499-511, 2003.

S. Kaptoge, C-reactive protein, fibrinogen, and cardiovascular disease prediction, N Engl J Med, vol.367, pp.1310-1320, 2012.

F. Massimo, European Guidelines on cardiovascular disease prevention in clinical practice, European Heart Journal, vol.37, pp.2315-2381, 2016.

E. Ohman, Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators, N Engl J Med, vol.335, pp.1333-1374, 1996.

E. M. Antman, Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes, N Engl J Med, 1996.

M. Grabowski, Prognostic value of B-type natriuretic peptide levels on admission in patients with acute ST elevation myocardial infarction, Acta Cardiol, vol.60, pp.537-579, 2005.

B. Lindahl, Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy, J Am Coll Cardiol, vol.45, pp.533-574, 2005.

J. Nilsson, Left ventricular remodeling in the first year after acute myocardial infarction and the predictive value of N-terminal pro brain natriuretic peptide, Am Heart J, vol.143, pp.696-702, 2002.

K. Eggers, Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome, J Am Coll Cardiol, vol.54, pp.357-64, 2009.

J. Perk, European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts), Eur Heart J, vol.33, issue.13, pp.1635-701, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00927636

M. Valgimigli, ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). The Task Force for the Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC), Eur Heart J, vol.2017, issue.3, pp.213-260, 2017.

E. Puymirat, Guidelines for the Management of Dyslipidaemias

G. G. Schwartz, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial, JAMA, vol.285, issue.13, pp.1711-1718, 2001.

S. M. Boekholdt, Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials, J Am Coll Cardiol, vol.64, issue.5, pp.485-494, 2014.

J. Fulcher, Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials, Lancet, vol.385, issue.9976, pp.1397-1405, 2015.

M. F. Piepoli, European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR), Eur Heart J, vol.37, issue.29, pp.2315-2381, 2016.

U. Landmesser and M. , Update of ESC/EAS Task Force on practical clinical guidance for PCSK9 inhibitors, Eur Heart J, vol.39, issue.14, pp.1131-1143, 2017.

, Principales dyslipidémies : stratégies de prise en charge, HAS Février, 2017.

S. Chatterjee, Early intravenous beta-blockers in patients with acute coronary syndrome a meta-analysis of randomized trials, Int J Cardiol, vol.168, pp.915-921, 2013.

J. J. Goldberger, Effect of beta-blocker dose on survival after acute myocardial infarction, J Am Coll Cardiol, vol.66, issue.13, pp.1431-1441, 2015.

S. Yusuf, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators, N Engl J Med, vol.342, pp.145-53, 2000.

K. Fox, The European trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study), Lancet, vol.362, pp.782-88, 2003.

M. A. Pfeffer, Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarc-tion complicated by heart failure, left ventricular dysfunction, or both, N Engl J Med, vol.349, issue.20, pp.1893-1906, 2003.

N. Girerd, Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial, Eur Heart J, vol.36, issue.34, pp.2310-2317, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01742988

B. Pitt, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med, vol.348, issue.14, pp.1309-1321, 2003.

J. A. Critchley, Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review, JAMA, vol.290, issue.1, pp.86-97, 2003.

D. Angelantonio and E. , Body-mass index and allcause mortality: individual participant-data meta-analysis of 239 prospective studies in four continents, Lancet, vol.388, pp.776-786, 2016.

J. A. Iestra, Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review, Circulation, vol.112, pp.924-934, 2005.

G. J. Balady, Core components of cardiac rehabilitation/ secondary prevention programs: 2007 update: A scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation, Circulation, vol.115, pp.2675-2682, 2007.

L. Anderson, Exercisebased cardiac rehabilitation for coronary heart disease: Cochrane systematic review and meta-analysis, J Am Coll Cardiol, vol.67, pp.1-12, 2016.

P. Libby, Inflammation in atherosclerosis: transition from theory to practice, Circ J, vol.74, pp.213-233, 2010.

B. Lattuca, L'inflammation dans l'infarctus, une nouvelle cible thérapeutique? Cardiologie pratique, 2018.

C. Roubille, Cardiovascular adverse effects of anti-inflammatory drugs, Anti-Inflamm Anti-Allergy Agents Med Chem, vol.12, pp.55-67, 2013.

P. Libby, Interleukin-1 Beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond, J Am Coll Cardiol, vol.70, pp.2-278, 2017.

P. M. Ridker, Antiinflammatory therapy with canakinumab for atherosclerotic disease, N Engl J Med, vol.377, pp.1-119, 2017.

C. Monpère, Recommandations de la Société française de cardiologie concernant la pratique de la réadaptation cardiovasculaire chez l'adulte, version 2. Archives des maladies du coeur et des vaisseaux, Tome, vol.95, issue.n°10, pp.963-997, 2002.

J. Myers, Exercise capacity and mortality among men referred for exercise testing, N Engl J Med, vol.346, pp.793-801, 2002.

M. Wei, Relationship between low cardio-respiratory fitness and mortality in normalweight, overweight and obese men, JAMA, vol.282, pp.1547-1553, 1999.

C. Handschin, The role of exercise and PGC-1alpha in inflammation and chronic disease, Nature, vol.454, pp.463-469, 2008.

P. Ba, Referentiel des bonnes pratiques de la réadaptation cardiaque de l'adulte en, 2011.

C. Handschin, The role of exercise and PGC-1alpha in inflammation and chronic disease, Nature, vol.454, pp.463-469, 2008.

H. Pilegaard, Exercise induces transient transcriptional activation of the PGC-1? gene in human skeletal muscle, J Physiol, vol.546, pp.851-858, 2003.

H. Pilegaard, Exercise induces transient transcriptional activation of the PGC-1? gene in human skeletal muscle, J Physiol, vol.546, pp.851-858, 2003.

F. P. Leung, Exercise, vascular wall and cardiovascular diseases. An update, Sports Med, vol.38, pp.1009-1033, 2008.

M. S. El-sayed, Exercise and training effects on blood haemostasis in health and disease: an update, Sports Med, vol.34, pp.181-200, 2004.

R. S. Taylor, Exercise-based rehabilitation for patients with . coronary heart disease: systematic review and meta-analysis of randomized . controlled trials, Am J Med, vol.116, issue.10, pp.682-692, 2004.

M. Piepoli, Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation, Eur J Cardiovasc Prev Rehabil, vol.17, issue.1, pp.1-17, 2010.

D. G. Cook, C-reactive protein concentration in children: relationship to adiposity and other cardio-vascular risk factors, Atherosclerosis, vol.149, pp.139-50, 2000.

D. Rader, Inflammatory markers of coronary risk, N Engl J Med, vol.343, pp.1179-82, 2000.

J. S. Yudkin, C-reactiveprotein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?, Arterioscler Thromb Vasc Biol, vol.19, pp.972-980, 1999.

V. Training-richard, Reduction in C-Reactive Protein Through Cardiac Rehabilitation and Exercise Training Exercise, vol.43, pp.1056-1061, 2004.

T. A. Lakka, Effect of exercise training on plasma levels of C-reactive protein in healthy adults: the HERITAGE Family Study, Eur Heart J, vol.26, pp.2018-2043, 2005.

R. V. Milani, Prevalence and profile of metabolic syndrome in patients following acute coronary events and effects of therapeutic lifestyle change with cardiac rehabilitation, Am J Cardiol, vol.92, pp.50-54, 2003.

S. Timothy, Exercise without Weight LossDoes Not Reduce C-Reactive Protein: The INFLAME Study, American College of Sports Medicine, pp.708-716, 2010.

P. Mlakar, The effect of short-term cardiac rehabilitation after acute myocardial infarction on high-sensitivity C-reactive protein, Metab Syndr Relat Disord, vol.12, issue.2, pp.149-55, 2014.

Y. Cottin, Specific profile and referral bias of rehabilitated patients after an acute coronary syndrome, J Cardiopulm Rehab, vol.24, pp.38-44, 2004.

D. Pavy, Cardiac rehabilitation after myocardial infarction in France: Still not prescribed enough. Ann de Cardiol, vol.63, pp.369-375, 2014.

M. Hanssen, French Registry on Acute ST-elevation and non ST-elevation Myocardial Infarction, pp.699-705, 2010.

K. Kotseva, EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries, Eur J Cardiovasc Prev Rehabil, vol.16, issue.2, pp.121-158, 2009.

A. J. Lee, The economics of cardiac rehabilitation and lifestyle modification: a review of literature, J Cardiopulm Rehabil Prev, vol.27, pp.135-177, 2007.

S. Papadakis, Economic evaluation of cardiac rehabilitation: a systematic review, Eur J Cardiovasc Prev Rehabil, vol.12, pp.513-533, 2005.

K. Jolly, Home-based cardiac rehabilitation compared with centre-based rehabilitation and usual care: a systematic review and meta-analysis, Int J Cardiol, vol.111, pp.343-51, 2006.

. Sfc, Recommandations du Groupe Exercice Réadaptation Sport (GERS) de la Société Française de Cardiologie concernant la pratique de la réadaptation cardiovasculaire chez l'adulte, version 3, 2011.

H. M. Dalal, Home based versus centre based cardiac rehabilitation: Cochrane systematic review and meta-analysis, BMJ, vol.340, p.5631, 2010.

C. Monpère, Recommandations de la Société française de cardiologie concernant la pratique de la réadaptation cardiovasculaire chez l'adulte, 82 version 2. Archives des maladies du coeur et des vaisseaux, vol.95, pp.963-997, 2002.

. Rapport-de-l'oms-europe, Therapeutic patient education-continuing education programmes for health care providers in the field of chronic disease

H. Recommandations, Education thérapeutique du patient. Définition, finalités et organisation. www.has-sante.fr

K. Kotseva, Cardiac rehabilitation for coronary patients: lifestyle, risk factor and therapeutic management. Results from the EUROASPIRE II survey, European Heart Journal Supplements, pp.17-26, 2004.

K. Kotseva, Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries, Lancet, vol.373, issue.9667, pp.929-969, 2009.

K. Kotseva, III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries, Eur J Cardiovasc Prev Rehabil, vol.16, issue.2, pp.121-158, 2009.

K. Kotseva, Treatment of patients with coronary heart disease fails to meet standards of european guidelines: results of EUROASPIRE surveys, Rev Esp Cardiol, vol.62, issue.10, pp.1095-1103, 2009.

N. Frasure-smith, Depression and 18 month prognosis after myocardial infarction, Circulation, vol.91, pp.999-1005, 1995.

C. Monpere, Return to work after cardiovascular rehabilitation in 128 coronary patients followed for 7 years. Results and medico-economic analysis, vol.93, pp.797-806, 2000.

B. S. Heran, Exercise-based cardiac rehabilitation for coronary heart disease, Cochrane Database Syst Rev, issue.7, p.1800, 2011.

P. Ponikowski, Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance: marker of abnormal cardiorespiratory reflex control and predictor of poor prognosis, Circulation, vol.103, pp.967-72, 2001.

T. Kavanagh, Prediction of long term prognosis in 12169 Men referred for cardiac rehabilitation, Circulation, vol.106, pp.666-671, 2002.

B. A. Franklin, Cardiorespiratory fitness: an independent and additive marker of risk stratification and health outcomes, Mayo Clin Proc, vol.84, pp.776-785, 2009.

F. Delahaye, Recommandations de la Société française de cardiologie concernant la prise en charge de l'infarctus du myocarde après la phase aiguë, Archives des maladies du coeur et des vaisseaux, vol.94, issue.7, 2001.

J. D. Neaton, Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group, Arch Intern Med, vol.152, pp.1490-1500, 1992.

Z. Reiner, EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) the European Atherosclerosis Society (EAS), Eur Heart J, vol.32, pp.1769-1818, 2011.

B. Mihaylova, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials, Lancet, vol.380, pp.581-590, 2012.

A. Pfutzner, High-sensitivity C-reactive prtein as cardiovascular risk marker in patients with diabetes mellitus, Diabetes Technol Ther, vol.8, issue.1, pp.28-36, 2006.

P. M. Ridker, Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events, N Engl J Med, vol.347, pp.1557-65, 2002.

M. A. Mendall, C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men, Eur Heart J, vol.21, pp.1584-90, 2000.

C. J. Lavie, Statin wars: emphasis on potency vs event reduction and safety?, Mayo Clin Proc, vol.82, issue.5, pp.539-542, 2007.

P. M. Ridker, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy, N Engl J Med, vol.352, issue.1, pp.20-28, 2005.

L. E. Pastormerlo, The bottleneck of cardiac rehabilitation for patients with coronary artery disease: How to overcome, European Journal of Preventive Cardiology, vol.25, issue.12, pp.1239-1241, 2018.

E. Bruckert, Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study, Cardiovasc Drugs Ther, vol.19, pp.403-414, 2005.

D. Stasi and S. L. , Effects of statins on skeletal muscle: a perspective for physical therapists, Phys Ther, vol.90, pp.1530-1542, 2010.

L. Belle, French Registry on Acute ST-elevation and non-ST-elevation Myocardial Infarction 2015 (FAST-MI 2015). Design and baseline data, Arch Cardiovasc Dis, vol.110, issue.6-7, pp.366-378, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01685342

C. P. Cannon, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes, N Engl J Med, vol.350, pp.1-495, 2004.

J. R. O'keefe, Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal, J Am Coll Cardiol, vol.43, pp.2-142, 2004.

P. Christopher, Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes, N Engl J Med, vol.372, pp.2387-2397, 2015.

S. Marc, Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease, N Engl J Med, vol.376, pp.1713-1722, 2017.

A. K. Gitt, Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II, Atherosclerosis, vol.266, pp.158-166, 2017.

J. Munkhaugen, The prevalence and predictors of elevated C-reactive protein after a coronary heart disease event, European Journal of Preventive Cardiology, vol.25, issue.9, pp.923-931, 2018.

V. M. Conraads, Combined endurance/resistance training reduces plasma TNF-alpha receptor levels in patients with chronic heart failure and coronary artery disease, Eur Heart J, vol.23, issue.23, pp.1854-60, 2002.

F. Cesari, Impact of a cardiac rehabilitation program and inflammatory state on endothelial progenitor cells in acute coronary syndrome patients, Int J Cardiol, vol.167, issue.5, pp.1854-1863, 2013.

S. Balen, Anti-inflammatory effects of exercise training in the early period after myocardial infarction, Coll Antropol, vol.32, issue.1, pp.285-91, 2008.

A. Aminlari, Association of cardiac rehabilitation with improvement in high sensitive C-reactive protein post-myocardial infarction, Iran Red Crescent Med J, vol.14, issue.1, pp.49-50, 2012.

R. V. Milani, Reduction in C-. reactive protein through cardiac rehabilitation exercise training, J Am Coll Cardiol, 2004.

S. Masoumeh, Effect of cardiac rehabilitation on inflammation: A systematic review and meta-analysis of controlled clinical trials, ARYA Atheroscler, vol.14, pp.85-95, 2018.

V. Richard, Reduction in C-Reactive Protein Through Cardiac Rehabilitation and Exercise Training, JACC, vol.43, issue.6, pp.1056-61, 2004.

T. Anzait, C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-Wave Acute Myocardial Infarction, Circulation, vol.96, pp.778-84, 1997.

J. Musial, Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia, Int J Cardiol, vol.77, pp.247-53, 2001.

P. M. Ridker, Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercho-lesterolemia, Circulation, vol.103, pp.1191-1194, 2001.

S. Kinlay, Low-density lipoprotein-dependent and -inde-pendent effects of cholesterol-lowering therapies on C-reactive protein: A meta-analysis, J Am Coll Cardiol, vol.49, pp.2003-2009, 2007.

J. S. Yudkin, Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link, Atherosclerosis, vol.148, pp.209-223, 2000.

J. S. Yudkin, C-reactiveprotein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?, Arterioscler Thromb Vasc Biol, vol.19, pp.972-980, 1999.

A. Tchernof, Weightloss reduced C-reactive protein levels in obese postmenopausal women, Circulation, vol.105, pp.564-573, 2002.

C. J. Lavie, Impact of cardiac rehabilitation on coronary risk factors, inflammation, and the metabolic syndrome in obese coronary patients, J Cardiometab Syndr, vol.3, issue.3, pp.136-176, 2008.

A. S. Wedell-neergaard, Low fitness is associated with abdominal adiposity and low-grade inflammation independent of BMI, Plos one, pp.177-89, 2018.

V. Richard, Reduction in C-Reactive Protein Through Cardiac Rehabilitation and Exercise Training, JACC, vol.43, issue.6, pp.190-198, 2004.

A. Leaf, Omega-3 fatty acids and cardiovascular disease, World Rev Nutr Diet, vol.89, pp.161-72, 2001.

H. Grimm, Regulatory potential of n-3 fatty acids in immunological and inflammatory processes, Br J Nutr, vol.87, issue.1, pp.59-67, 2002.

V. M. Conraads, Combined endurance/resistance training reduces plasma TNF-alpha receptor levels in patients with chronic heart failure and coronary artery disease, Eur Heart J, vol.23, issue.23, pp.1854-60, 2002.

Y. J. Kim, Beneficial effects of cardiac rehabilitation and exercise after percutaneous coronary intervention on hsCRP and inflammatory cytokines in CAD patients, Pflugers Arch, vol.455, issue.6, pp.1081-1089, 2008.

Y. O. Shin, Effect of cardiac rehabilitation and statin treatment on anti-HSP antibody titers in patients with coronary artery disease after percutaneous coronary intervention, Int Heart J, vol.47, issue.5, pp.671-82, 2006.

, Au moment d'être admise à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité.Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences

, Je donnerai mes soins à l'indigent et à quiconque me les demandera

, Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire

, Admise dans l'intimité des personnes, je tairai les secrets qui me seront confiés. Reçue à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je préserverai l'indépendance nécessaire à l'accomplissement de ma mission

, Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses

, que je sois déshonorée et méprisée si j'y manque